zopapogene imadenovec-drba (PAPZIMEOS)
zopapogene imadenovec-drba is an FDA-licensed reference biologic from Precigen, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
PAPZIMEOS zopapogene imadenovec-drba
Precigen, Inc.
- Approved
- Aug 14, 2025
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for zopapogene imadenovec-drba, in chronological order.
Reference approval
Approval date of the reference zopapogene imadenovec-drba product.
10 mo ago
Frequently asked questions
Are there biosimilars approved for zopapogene imadenovec-drba (PAPZIMEOS)?
No 351(k) biosimilars or interchangeable biosimilars referencing zopapogene imadenovec-drba are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.